Sanofi said it will stop seeking approval for amlitelimab in atopic dermatitis, citing that the OX40-ligand antibody would not meaningfully improve care for patients with moderate to severe disease. The decision marks an about-face for a program that had been positioned as a potential successor path to Dupixent.